(MT Newswires) -- Kasim Kutay, CEO of Novo Holdings, has announced that the group is to step up its M&A activity, with a particular focus on the life sciences and healthcare sector. The company is looking to avoid areas already covered by Novo Nordisk, such as obesity.  Novo Nordisk aims to steer investments through to the end of the decade, with a strong focus on Asian markets, despite high valuations.

Bloomberg videos